Literature DB >> 6576995

Studies on the differentiation inducers of myeloid leukemic cells. III. Spicamycin, a new inducer of differentiation of HL-60 human promyelocytic leukemia cells.

Y Hayakawa, M Nakagawa, H Kawai, K Tanabe, H Nakayama, A Shimazu, H Seto, N Otake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6576995     DOI： 10.7164/antibiotics.36.934

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  4 in total

Review 1.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.

Authors:  S M Gadgeel; R R Boinpally; L K Heilbrun; A Wozniak; V Jain; B Redman; M Zalupski; R Wiegand; R Parchment; P M LoRusso
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

3.  Draft Genome Sequence of an Anicemycin Producer, Streptomyces sp. TP-A0648.

Authors:  Hisayuki Komaki; Akira Hosoyama; Akane Kimura; Natsuko Ichikawa; Yasuhiro Igarashi
Journal:  Genome Announc       Date:  2017-01-12

4.  Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein.

Authors:  W J Zhang; K Ohnishi; H Yoshida; L Pan; L Maksumova; F Muratkhodjaev; J M Luo; K Shigeno; S Fujisawa; K Naito; S Nakamura; K Shinjo; A Takeshita; R Ohno
Journal:  Jpn J Cancer Res       Date:  2000-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.